Pediatric Aerosol Therapy: New Devices and New Drugs

Author: Rubin, Bruce K

Source: Respiratory Care, Volume 56, Number 9, September 2011 , pp. 1411-1423(13)

Publisher: The Journal Respiratory Care Company

Buy & download fulltext article:

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

Abstract:

The lung and conducting airways are ideal portals for drug delivery. The airways are easily accessible by oral or nasal inhalation; the airway and alveolar surface is large, allowing for drug dispersion; and many drugs do not cross the airway-blood barrier, permitting the use of higher topical drug doses for airway disease than would be practical with systemic administration. On the other hand, alveolar deposition of drugs allows rapid absorption into the pulmonary circulation and back to the left heart and systemic distribution, bypassing the intestinal tract and liver inactivation. Recently, there has been a feast of new aerosol devices and drug formulations that promise the effective delivery of an amazing array of medications far beyond pressurized metered-dose inhalers and nebulizers and asthma medicines.

Keywords: aerosol devices; antibiotics; children; gene therapy; medication adherence; mucolytics; nebulizers

Document Type: Research Article

DOI: http://dx.doi.org/10.4187/respcare.01246

Affiliations: Department of Pediatrics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA

Publication date: September 1, 2011

More about this publication?
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page